Trial · NCT03382600
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 72.2 | 95% Confidence Interval 58.4 to 83.5 | Percentage of participants | |
| Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 80.4 | 95% Confidence Interval 66.1 to 90.6 | Percentage of participants | |
| ORR According to Immune-related Response Evaluation Criteria In Solid Tumors (iRECIST) Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 72.2 | 95% Confidence Interval 58.4 to 83.5 | Percentage of participants | |
| ORR According to Immune-related Response Evaluation Criteria In Solid Tumors (iRECIST) Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 80.4 | 95% Confidence Interval 66.1 to 90.6 | Percentage of participants | |
| Duration of Response (DOR) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 10.6 | 95% Confidence Interval 5.6 to NA | months | |
| Duration of Response (DOR) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 9.5 | 95% Confidence Interval 4.7 to 15.3 | months | |
| DOR According to iRECIST Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 10.6 | 95% Confidence Interval 5.6 to NA | months | |
| DOR According to iRECIST Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 9.5 | 95% Confidence Interval 4.7 to NA | months | |
| Disease Control Rate (DCR) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 96.3 | 95% Confidence Interval 87.3 to 99.5 | Percentage of participants | |
| Disease Control Rate (DCR) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 97.8 | 95% Confidence Interval 88.5 to 99.9 | Percentage of participants | |
| DCR According to iRECIST 1.1 Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 96.3 | 95% Confidence Interval 87.3 to 99.5 | Percentage of participants | |
| DCR According to iRECIST 1.1 Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 97.8 | 95% Confidence Interval 88.5 to 99.9 | Percentage of participants | |
| Time to Response (TTR) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 1.5 | Inter-Quartile Range 1.3 to 5.5 | months | |
| Time to Response (TTR) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 1.5 | Inter-Quartile Range 1.2 to 2.9 | months | |
| TTR According to iRECIST 1.1 Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 1.5 | Inter-Quartile Range 1.3 to 5.5 | months | |
| TTR According to iRECIST 1.1 Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 1.5 | Inter-Quartile Range 1.2 to 2.9 | months | |
| Progression-free Survival (PFS) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 9.4 | 95% Confidence Interval 6.6 to 12.6 | months | |
| Progression-free Survival (PFS) According to RECIST 1.1 Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 8.3 | 95% Confidence Interval 5.8 to 15.3 | months | |
| PFS According to iRECIST 1.1 Assessed by BICR | Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 9.4 | 95% Confidence Interval 6.6 to 12.6 | months | |
| PFS According to iRECIST 1.1 Assessed by BICR | Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 10.9 | 95% Confidence Interval 6.7 to NA | months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03382600/results